ArticleBMC nephrology2025
Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPatients undergoing peritoneal dialysis are at high risk of infection, which significantly impacts morbidity and mortality. This retrospective study aimed to evaluate the association of thymopentin use with infection risk, immune function, and inflammatory markers in peritoneal dialysis patients.
methodsClinical data from 100 patients undergoing peritoneal dialysis were collected and analyzed. According to the treatment regimens received, patients were divided into a control group (standard therapy) and a thymopentin group (standard therapy combined with thymopentin). Thymopentin was administered subcutaneously at a dose of 10 mg daily for the first 5 days, followed by 10 mg three times per week (Monday, Wednesday, and Friday) for 23 consecutive weeks. Patients were followed for a total of 48 weeks. Infection rates, immune function, and levels of inflammatory markers were compared between the two groups.
resultsThe thymopentin group demonstrated a lower infection incidence than the control group (0.73 vs. 1.00 per person-year). Thymopentin use was associated with significantly reduced overall infection rates (P < 0.001) and peritonitis (P = 0.031). Multivariate analysis confirmed a lower infection risk (HR = 0.54, 95% CI: 0.30-0.95; P = 0.034). Inflammatory markers showed favorable changes: interleukin-2 receptor (IL-2R) levels increased at 12 and 24 weeks (P = 0.002 and 0.020), interleukin-6 (IL-6) decreased at 12 weeks (P = 0.036). Serum albumin rose at both time points (P = 0.023 and 0.040). No significant changes were observed in CD3⁺/CD4⁺ or CD8⁺ T cells or the CD4/CD8 ratio.
conclusionThymopentin use was associated with reduced infection risk and favorable changes in inflammatory and nutritional markers among peritoneal dialysis patients. These findings suggest potential benefits of Thymopentin in this population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.